Study found that giving rituximab once weekly for a month provided the same benefits as 18 months of daily immunosuppressive therapy.

Friday, July 16, 2021 NIAID Research Informs Guideline for Treating People with ANCA-Associated Vasculitis Projected image (focus stacked) of the vascular branches in the retina at the back of the eye. Credit: Bryan William Jones A NIAID-funded study contributes to the evidence for a new guideline on how to induce remission and treat relapse of a rare, severe autoimmune disease called ANCA-associated vasculitis. The study found in 2013 that giving the drug rituximab to people with ANCA-associated vasculitis once weekly for a month provided the same benefits as 18 months of daily immunosuppressive therapy. The new guideline recommends that doctors use rituximab as a first-line drug to induce and maintain remission of active, severe ANCA-associated vasculitis. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107